Enveric Biosciences (ENVB) Other Accumulated Expenses (2015 - 2025)
Enveric Biosciences (ENVB) posted Other Accumulated Expenses of $99875.0 for Q4 2025, little changed sequentially from $99875.0 in Q2 2025, and down 57.12% YoY from $232891.0 in Q4 2024.
Enveric Biosciences (ENVB) Other Accumulated Expenses (2015 - 2025) Analysis & Trends
Enveric Biosciences has reported Other Accumulated Expenses for 10 years, with the latest figure at $99875.0 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 57.12% year-over-year to $99875.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $99875.0 (down 57.12% YoY) and the FY2025 annual result came in at $99875.0, down 57.12% from the prior year.
- Other Accumulated Expenses was little changed at $99875.0 in Q4 2025 per ENVB's latest filing, from $99875.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.8 million in Q2 2023 and troughed at $12210.0 in Q1 2024.
- A 4-year average of $377817.2 and a median of $99875.0 in 2025 frame the typical range for Other Accumulated Expenses.
- The widest YoY moves for Other Accumulated Expenses: up 1193.84% in 2024, down 99.01% in 2024.
- Over 4 years, Other Accumulated Expenses stood at $851008.0 in 2022, then tumbled by 97.88% to $18000.0 in 2023, then jumped by 1193.84% to $232891.0 in 2024, then sank by 57.12% to $99875.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $99875.0, $99875.0, and $101375.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 99,875.00 |
| Jun 30, 2025 | 99,875.00 |
| Mar 31, 2025 | 101,375.00 |
| Dec 31, 2024 | 232,891.00 |
| Sep 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 12,210.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | 18,000.00 |
| Dec 31, 2022 | 851,008.00 |
| Sep 30, 2020 | 1.91 Mn |
| Jun 30, 2020 | 1.92 Mn |
| Mar 31, 2020 | 2.18 Mn |
| Dec 31, 2019 | 1.99 Mn |
| Sep 30, 2019 | 1.55 Mn |
| Jun 30, 2019 | 1.80 Mn |
| Mar 31, 2019 | 1.63 Mn |
| Dec 31, 2018 | 1.70 Mn |